HTA Method Shifts & RWE Integration

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are hitting at a critical inflection point for how we generate and apply evidence.

MarcusSame here. We're looking at FDA's draft guidance on using real-world data in post-marketing studies — which could reshape how we monitor drug safety and effectiveness after launch. Then CMS's proposed changes to Medicare Advantage star ratings methodology — directly impacting how providers are measured on quality metrics. And finally, the integration of environmental sustainability metrics into value assessments — a question of how we define 'value' in 2026.

SaraThat first one on FDA guidance is particularly interesting. The budget impact question when you shift from controlled trials to real-world data is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA's draft guidance on real-world evidence for post-marketing studies. The core shift here is moving beyond traditional RCTs to leverage real-world data for safety and effectiveness monitoring. This could significantly reduce the time and cost of post-approval surveillance, especially for rare diseases where RCTs remain challenging.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the operational burden this places on manufacturers. Generating high-quality RWE that meets regulatory standards requires massive infrastructure investment. The part that gives me pause is how this will interact with existing pharmacovigilance systems.

MarcusThat connects to something I keep coming back to: the signal-to-noise problem in real-world data. The guidance emphasizes data quality, but in practice, we're seeing RWE studies struggle with confounding variables that RCTs control for. I wonder if that's the full picture though — the FDA is clearly signaling that RWE isn't just supplementary anymore.

SaraThe part that gives me pause is the reimbursement implications. If payers start accepting RWE for coverage decisions, we need entirely new frameworks for evaluating its validity. That's fair, though I think payers would see it differently — the risk of real-world data being misinterpreted is substantial.

MarcusThat's a real tension point. Historically, payers have been more skeptical of RWE than regulators. The methodology needs to evolve to address that. Honestly, this one caught me off guard — the FDA's willingness to accept RWE for primary endpoints in some cases is a significant departure.

SaraI'd push back slightly on that. The guidance specifically limits RWE to supportive evidence, not primary endpoints. But what's striking here is how it forces manufacturers to develop new capabilities in data generation and analysis. That's a structural shift in HEOR teams.

MarcusExactly. And the budget impact question Sara raised earlier is crucial. If RWE studies become mandatory, the cost of compliance could reshape evidence generation budgets. Let's move to CMS's Medicare Advantage changes.

SaraCMS's proposed changes to Medicare Advantage star ratings methodology deserve attention. The core shift is adding new quality measures focused on social determinants of health and chronic disease management. This directly impacts how providers are evaluated and reimbursed.

MarcusThat's one read — I'd frame it slightly differently. What's really interesting is how this creates new pathways for innovative therapies to demonstrate value. If a drug addresses social determinants or improves chronic disease outcomes, it could directly impact star ratings and provider adoption.

SaraThat's fair, though I think payers would see it differently. The operational hurdles are significant. CMS is essentially asking providers to collect and report entirely new categories of data. The opportunity cost here is substantial — resources diverted from clinical care to documentation.

MarcusThe part that gives me pause is how this interacts with value-based contracting. If star ratings become more important, manufacturers might need to develop evidence packages specifically for these new measures. That's a strategic shift in evidence generation.

SaraI wonder if that's the full picture though. The real question is whether these new measures actually correlate with better patient outcomes or just create more administrative burden. Historically, CMS quality measures have shown mixed results in predicting real-world effectiveness.

MarcusThat connects to something I keep coming back to: the tension between process measures and outcomes. The draft guidance emphasizes process measures for social determinants, which are easier to quantify but may not capture actual impact. This could lead to perverse incentives where providers focus on documentation rather than meaningful change.

SaraThe part that gives me pause is the budget impact. If star ratings determine bonus payments, and new measures are harder to achieve, we might see reduced bonuses overall. That would flow through to provider networks and potentially patient access. Honestly, this one caught me off guard — the breadth of the proposed changes is unprecedented.

MarcusExactly. And for manufacturers, it creates new evidence needs. Let's discuss digital health integration challenges next.

MarcusThe third topic: HTA data integration challenges with digital health. As digital therapeutics and remote monitoring become more prevalent, HTA bodies are struggling with how to evaluate these technologies. The core issue is measuring clinical utility in real-world settings.

SaraThat's one read — I'd frame it slightly differently. What's really interesting is the methodological gap. HTA frameworks were designed for drugs and devices with clear endpoints, not for interventions that continuously generate data streams. The opportunity cost here is significant — HTA resources stretched thin across new technologies.

MarcusThat's a real tension point. I'd push back slightly on the resource argument. The deeper challenge is defining appropriate endpoints for digital health. Many digital interventions focus on behavior change rather than hard clinical outcomes, which HTA bodies struggle to value.

SaraThe part that gives me pause is the reimbursement implications. If HTA bodies can't evaluate these technologies, they might default to traditional cost-effectiveness models that don't capture their full value. That's fair, though I think payers would see it differently — the risk of overpaying for unproven interventions is substantial.

MarcusThat connects to something I keep coming back to: the need for new HTA methodologies. We're seeing some early attempts at value frameworks for digital health, but they're inconsistent across jurisdictions. This creates uncertainty for manufacturers developing these technologies.

SaraI wonder if that's the full picture though. The real challenge is data ownership and privacy. Digital health technologies generate massive amounts of patient data, but HTA bodies lack the infrastructure to securely access and analyze it. That's a structural barrier to evidence generation.

MarcusExactly. And the budget impact question Sara raised earlier is crucial. If HTA processes become more complex for digital health, the cost of evidence generation increases. This could disadvantage smaller companies developing innovative digital solutions. Let's move to sustainability metrics.

SaraFinally, environmental sustainability metrics in value assessments. A growing number of HTA bodies are considering carbon footprint and environmental impact in their evaluations. This directly challenges traditional cost-effectiveness frameworks.

MarcusThat's one read — I'd frame it slightly differently. What's really interesting is how this expands the definition of 'value' beyond health outcomes. For manufacturers, this creates new evidence needs around environmental impact throughout the product lifecycle.

SaraThat's fair, though I think payers would see it differently. The methodological challenges are enormous. How do you quantify the value of reduced carbon emissions? The opportunity cost here is significant — resources diverted from clinical evidence to sustainability assessments.

MarcusThe part that gives me pause is the global inconsistency. Some HTA bodies are actively developing sustainability metrics, while others ignore them entirely. This creates regulatory divergence that manufacturers must navigate.

SaraI'd push back slightly on the inconsistency argument. The deeper issue is the lack of standardized methodologies. Until HTA bodies agree on how to measure and value environmental impact, this will remain a niche consideration. That's a real barrier to widespread adoption.

MarcusThat connects to something I keep coming back to: the patient perspective. While sustainability is important, patients ultimately care about health outcomes. The challenge is balancing these competing priorities in value assessments. Honestly, this one caught me off guard — the speed at which this has moved from fringe to mainstream is remarkable.

SaraExactly. And for manufacturers, it requires new capabilities in lifecycle assessment and environmental data management. This is becoming a strategic consideration in evidence generation.

SaraA lot to think about today. I'll be watching how HTA bodies develop standardized methodologies for digital health evaluation — that's the next frontier in evidence generation.

MarcusSame — and for me the thread running through today is the increasing complexity of evidence requirements. We're moving beyond traditional endpoints to broader value definitions, which challenges how we generate and evaluate evidence.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.